dihexa human clinical trial safety Dihexa: Benefits, Evidence, & Legal Status Selective Safety Data Collection in

This testing approach helps support consistency, transparency, and reliable documentation across research peptide vials, peptide capsules, liquid peptide sprays, and research compound formulations

71 LojoN.RasicZ.Zenko SeverA.KolencD.VukusicD.DrmicD.et al (2016)

Given the restored myotendinous junction [13], to approach achievable muscle-to-bone reattachment, the innate effect of BPC 157 (i.e., the successful recovery of the quadriceps muscle myotendinous junction) [13] largely departs from complex delivery (i.e., via magnetic force) [58], local application, and the use of various carriers [59,60,61,62,63]

Even if BPC-157 is ultimately added to the list, it would remain an unapproved drug

BPC-157 or TB-500 may be one part of a broader conversation, but they should not replace foundational care